New pain pill LTG-321 enters first human safety tests

NCT ID NCT07110610

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-stage study tests an experimental oral drug called LTG-321 in 236 healthy adults aged 18-55. The main goal is to check safety and how the body processes the drug. Researchers will also measure pain tolerance using a cold water test and see if a high-fat meal affects drug levels. This is a first step to see if LTG-321 is safe enough for future pain studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LTG-321 (oral drug)

What this could lead to

If successful, this could pave the way for further studies of LTG-321 as a potential pain treatment.

What could go wrong

This is a very early Phase 1 trial in healthy people, not patients. It primarily tests safety, not effectiveness. The drug may not work or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • New Zealand Clinical Research

    Christchurch, New Zealand